PPBT vs. SPRB, HCWB, SYBX, NRSN, EGRX, MTVA, IPA, GOVX, NERV, and CLRB
Should you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Spruce Biosciences (SPRB), HCW Biologics (HCWB), Synlogic (SYBX), NeuroSense Therapeutics (NRSN), Eagle Pharmaceuticals (EGRX), MetaVia (MTVA), ImmunoPrecise Antibodies (IPA), GeoVax Labs (GOVX), Minerva Neurosciences (NERV), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry.
Purple Biotech vs.
Purple Biotech (NASDAQ:PPBT) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations, community ranking and risk.
Purple Biotech has higher earnings, but lower revenue than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.
Purple Biotech presently has a consensus price target of $33.00, suggesting a potential upside of 941.01%. Spruce Biosciences has a consensus price target of $2.38, suggesting a potential upside of 465.48%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than Spruce Biosciences.
9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 3.0% of Purple Biotech shares are held by company insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Purple Biotech had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.00 beat Purple Biotech's score of -0.88 indicating that Spruce Biosciences is being referred to more favorably in the news media.
Purple Biotech has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.
Purple Biotech has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Purple Biotech's return on equity of -55.86% beat Spruce Biosciences' return on equity.
Spruce Biosciences received 22 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 94.44% of users gave Purple Biotech an outperform vote while only 54.93% of users gave Spruce Biosciences an outperform vote.
Summary
Purple Biotech beats Spruce Biosciences on 10 of the 17 factors compared between the two stocks.
Get Purple Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Purple Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:PPBT) was last updated on 2/22/2025 by MarketBeat.com Staff
